Article Text

Download PDFPDF

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification
  1. Drew Hotson1,
  2. Ryan Alvarado1,
  3. Andrew Conroy1,
  4. Santosh Putta1,
  5. Ester Simeone2,
  6. Assunta Esposito2,
  7. Mariaelena Capone2,
  8. Gabriele Madonna2,
  9. Antonio M Grimaldi2,
  10. David Rosen1,
  11. Spencer Liang1,
  12. Alessandra Cesano1,
  13. Paolo A Ascierto2,3 and
  14. Rachael Hawtin1,3
  1. Aff1 grid.429615.dNodality, Inc. South San Francisco CA USA
  2. Aff2 G. Pascale National Tumor Foundation Institute Naples Italy
  3. Aff3 Co-senior authors South San Francisco CA USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Ipilimumab, an anti-CTLA-4 monoclonal antibody, is approved for treatment of unresectable/metastatic melanoma. Treatment benefits only a subset of patients (pts) and is associated with significant adverse effects. Biomarkers of pt response are needed. Single cell network profiling (SCNP) is a multiparametric flow cytometry-based assay that quantitatively measures both phenotypic markers and changes in intracellular signaling proteins in response to modulation, enabling analysis of cell signaling networks.


Functional proteomic profiling of immune signaling pathways in PBMC subsets in healthy donors and pts with metastatic melanoma receiving ipilumumab treatment.


3 healthy and 13 melanoma pt cryopreserved samples, (7 pre-treatment (pre-Tx), 6 post-treatment (post-Tx)) were analyzed. Cells were assessed for viability, cell subset frequencies and signaling in response to modulation. A node is the combination of modulator and intracellular readout (e.g. IL-6 -> p-STAT3). Cytokine, TCR- or FcγR-induced activation of STAT1, 3, 5, CD3ζ and Erk was evaluated in immune cell populations and comparisons made based on disease, treatment time point and clinical responses.


Compared to healthy, melanoma monocytes displayed lower IL-10->p-STAT1, IL-10->p-STAT3, IL-6->p-STAT1, IL-6->p-STAT3 and FcγR->p-Erk. Similarly, TCR->p-CD3ζ was reduced most prominently in CD45RA- CD4+ and CD4- T cells. These data suggest hyporesponsivity of circulating immune cell subsets in the innate and adaptive arms of the immune response in melanoma pts. The same observations pertained to melanoma samples independent from administration of, or clinical response to, treatment. Effects of treatment on T cell signaling were observed compared to healthy donors and pre-Tx samples. Post-Tx samples had diminished TCR->p-Erk, TCR->p-CD3ζ in CD4+ and CD4- more prominently in CD45RA+ than CD45RA- subsets and diminished IL-15->p-STAT5 in CD4- T cells. No markers associated with clinical response to ipilumumab. In samples from non-responsive pts, the level of basal p-Erk in CD45RA+ CD4+ T cells and the percentage of Treg was higher compared to those of complete responders and healthy donors.


SCNP analysis of PBMC from healthy donors and melanoma pts pre-Tx and post-Tx identified signaling differences between melanoma and healthy and between pre- and post-Tx. Candidate predictive biomarkers for patient stratification will be evaluated in subsequent larger studies.